Nutritional Value of Tropical Plant Seeds

Modification of Seed Composition to Promote Health and Nutrition

Volumn , Issue , 2015, Pages 39-53

  Ezeagu, Ikechukwu E ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941811775     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Schantz, E.J. and Johnson, E.A. (1997). Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 40 (3): 317-327.
2. Carruthers, J.D. and Carruthers, J.A. (1992). Treatment of glabellar frown lines with C. Botulinum-a exotoxin. J Dermatol Surg Oncol 18: 17-21.
3. Carruthers, A. (2002). Botulinum toxin type a: history and current cosmetic use in the upper face. Dis Mon 48: 299-322.
4. American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank statistics. American Society for Aesthetic Plastic Surgery website. http://www.surgery.org/sites/default/files/ASAPS-Stats2015.pdf.
5. Hambleton, P. (1992). Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 239 (1): 16-20.
6. Panjwani, N., O'Keeffe, R., and Pickett, A. (2008). Biochemical, functional and potency characteristics of type a botulinum toxin in clinical use. Botulinum J 1 (1): 153-166.
7. Carruthers, J., Fagien, S., Matarasso, S.L. et al. (2004). Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 114 (suppl 6): 1S-22S.
8. Goodman, G. (1998). Botulinum toxin for the correction of hyperkinetic facial lines. Australas J Dermatol 39: 158-163.
9. Carruthers, A. and Carruthers, J. (1998). Clinical indications and injection technique for the cosmetic use of botulinum a exotoxin. Dermatol Surg 24: 1189-1194.
10. Xeomin(incobotulinum toxin A) [prescribing information]. Frankfurt am Main: Merz Pharmaceuticals, LLC; 2013.
11. Dysport®(abobotulinum toxin A) [prescribing information]. Boulogne-Billancourt: Ipsen Biopharm Ltd; 2012.
12. Ipsen, Ltd. Dysport Summary of Product Characteristics [webpage on the Internet]. Surrey, UK: Datapharm Communications Ltd; 2013. Available from: www.medicines.org.uk/emc/medicine/870. Accessed July 13, 2013.
13. BOTOX® (onabotulinumtoxinA) [prescribing information]. Irvine, CA:Allergan, Inc.; 2013.
14. Hatheway, C. (1989). Bacterial sources of clostridial neurotoxins. In: Botulinum Neurotoxin and Tetanus Toxin (ed. L.L. Simpson), 4-24. San Diego, CA:Academic Press.
15. Inoue, K., Fujinaga, Y., Watanabe, T. et al. (1996). Molecular composition of Clostridium botulinum type a progenitor toxins. Infect Immun 64 (5): 1589-1594.
16. Eisele, K.H., Fink, K., Vey, M. et al. (2011). Studies on the dissociation of botulinum neurotoxin type a complexes. Toxicon 57 (4): 555-565.
17. Chen, F., Kuziemko, G.M., Amersdorfer, P. et al. (1997). Antibody mapping to domains of botulinum neurotoxin serotype a in the complexed and uncomplexed forms. Infect Immun 65 (5): 1626-1630.
18. Jiang, H.Y., Chen, S., Zhou, J. et al. (2014). Diffusion of two botulinum toxins type a on the forehead: doubleblinded, randomized, controlled study. Dermatol Surg 40: 184-192.
19. Göschel, H., Wohlfarth, K., Frevert, J. et al. (1997). Botulinum a toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 147 (1): 96-102.
20. Kukreja, R., Chang, T.W., Cai, S. et al. (2009). Immunological characterization of the subunits of type a botulinum neurotoxin and different components of its associated proteins. Toxicon 53 (6):616-624.
21. Joshi, S.G., Elias, M., Singh, A. et al. (2011). Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. Neuroscience 179: 208-222.
22. Jiang, H.Y., Chen, S., Zhou, J. et al. (2014). Diffusion of two botulinum toxins type a on the forehead: doubleblinded, randomized, controlled study. Dermatol Surg 40: 184-192.
23. McLellan, K., Das, R.E., Ekong, T.A. et al. (1996). Therapeutic botulinum type a toxin: factors affecting potency. Toxicon 34 (9): 975-985.
24. Cliff, S.H., Judodihardjo, H., and Eltringham, E. (2008). Different formulations of botulinum toxin type a have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 7 (1): 50-54.
25. Pickett, A., Dodd, S., and Rzany, B. (2008). Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther 10 (3): 181-183.
26. Carruthers, A., Carruthers, J., and Said, S. (2005). Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 31 (4): 414-422. discussion 422. Biologics.
27. Ascher, B., Zakine, B., Kestemont, P. et al. (2004). A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin a in the treatment of glabellar lines. J Am Acad Dermatol 51 (2): 223-233.
28. Fulford-Smith, A., Gallagher, C.J., and Brin, M.F. (2013). Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Derm Surg 39 (7):1118-1119.
29. Sampaio, C., Costa, J., and Ferreira, J.J. (2004). Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19 (Suppl 8):S129-S136.
30. Alam, M., Bolotin, D., Carruthers, J. et al. (2015). Consensus statement regarding storage and reuse of previously reconstituted neuromodulators. Dermatol Surg 41: 321-326.
31. Wieder, J.M. and Moy, R.L. (1998). Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region. Dermatol Surg 24: 1172-1174.
32. Frankel, A.S. and Kamer, F.M. (1998). Chemical browlift. Arch Otolaryngol Head Neck Surg 124: 321-323.
33. Huilgol, S.C., Carruthers, A., and Carruthers, J.D. (1999). Raising eyebrows with botulinum toxin. Dermatol Surg 25: 373-376.
34. Huang, W., Rogachefsky, A.S., and Foster, J.A. (2000). Browlift with botulinum toxin. Dermatol Surg 26: 55-60.
35. Gordon, R.W. (2009). BOTOX cosmetic for lip and perioral enhancement. Dent Today 28: 94-97.
36. Semchyshyn, N. and Sengelmann, R.D. (2003). Botulinum toxin a treatment of perioral rhytides. Dermatol Surg 29:490-495.
37. Carruthers, J. and Carruthers, A. (2003). Aesthetic botulinum a toxin in the mid and lower face and neck. Dermatol Surg 29: 468-476.
38. Beer, K., Yohn, M., and Closter, J. (2005). A double-blinded, placebo-controlled study of Botox for the treatment of subjects with chin rhytids. J Drugs Dermatol 4: 417-422.
39. Carruthers, J. and Carruthers, A. (2004). Botulinum toxin a in the mid and lower face and neck. Dermatol Clin 22: 151-158.
40. Hoefflin, S.M. (1998). Anatomy of the platysma and lip depressor muscles. A simplified mnemonic approach. Dermatol Surg 24: 1225-1231.
41. Matarasso, A. and Matarasso, S.L. (2003). Botulinum a exotoxin for the management of platysma bands. Plast Reconstr Surg 112 (suppl 5): 138S-140S.
42. Kane, M.A. (2003). Nonsurgical treatment of platysma bands with injection of botulinum toxin a revisited. Plast Reconstr Surg 112 (suppl 5):125S-126S.
43. Batniji, R.K. and Falk, A.N. (2004). Update on botulinum toxin use in facial plastic and head and neck surgery. Curr Opin Otolaryngol Head Neck Surg 12: 317-322.
44. Hsu, T.S., Dover, J.S., Kaminer, M.S. et al. (2003). Why make patients exercise facial muscles for 4 hours after botulinum toxin treatment? Arch Dermatol 139: 948.